Haleon And 2 British AI Healthcare Stocks To Watch

Trade in AI related products is helping to offset wider disruptions in global commerce, according to the WTO, and that tailwind is reshaping how healthcare and technology intersect. For UK investors, this growing flow of capital and equipment into AI tools creates an opening to back companies working on faster diagnoses and smarter treatment decisions. This article highlights three stocks from a specialist AI healthcare screener that tap into that trend.

The three stocks in this article are just a starting sample from the idea. The full screen surfaces 5 more AI driven healthcare companies with equally compelling narratives that are not covered below. To see the complete picture and identify which opportunities fit your own risk, time horizon, and conviction level, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Overview: Haleon is a global consumer healthcare group using its Microsoft AI partnership to refine product development, supply chains, and personalised digital health services across its established OTC brands.

Operations: Haleon generates revenue of £3.8b in North America, £2.6b in Asia Pacific, and £4.7b across Europe, the Middle East, Africa, and Latin America.

Market Cap: £29.9b

Haleon brings AI into everyday healthcare decisions by pairing its household OTC portfolio with Microsoft powered data tools that aim to sharpen everything from product design to shelf availability.

"Artificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research."

For Haleon, the key question is what happens when that push for smarter, AI informed decisions encounters an unresolved pressure on future profitability and pricing power.

If that profitability squeeze is front of mind, full narrative for Haleon to see how Haleon's AI push could reshape pricing power and long term earnings potential.

IXICO (AIM:IXI)

Overview: IXICO runs an AI-enabled neuroimaging platform and imaging CRO services that help drugmakers analyse brain scans for complex neurological diseases.

Operations: IXICO generates £7.3 million of revenue from Medical Labs & Research services focused on neuroimaging data, biomarkers, and trial analytics.

Market Cap: £16 million

IXICO plugs directly into the AI in healthcare theme by using algorithms to read MRI, PET and SPECT brain scans for drug trials in Alzheimer’s and other neurological conditions. However, the company is still loss making with rising losses and shareholder dilution, so the real appeal hinges on whether growing demand for AI-driven imaging can outrun that one unresolved pressure on future returns.

If you think that trade off might be turning, the 1 key reward and 3 important warning signs (2 are major!) could show whether IXICO’s AI opportunity is starting to decouple from those funding pressures.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical group that develops and sells prescription medicines across oncology, cardiovascular, respiratory, vaccines, immune and rare disease therapies, increasingly weaving AI into cancer research and drug development partnerships.

Operations: AstraZeneca generates US$61.4b of revenue from its Pharmaceuticals segment, reflecting a broad portfolio of prescription medicines across multiple therapy areas.

Market Cap: £188.2b

AstraZeneca matters for this AI healthcare screen because its oncology unit is not just using data tools at the margins; it is building AI directly into how future cancer drugs are discovered, tested, and matched to patients.

"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."

What really shifts the risk reward here is how one still unresolved pressure on future oncology returns collides with that AI heavy pipeline.

That unresolved pressure is exactly why the full narrative for AstraZeneca digs into how AstraZeneca’s AI heavy oncology work could be quietly accelerating value, even as headline risks mask the shift.

Seeking Fresh Alternatives Beyond Healthcare AI?

Some of the most interesting opportunities often move first. Before the next breakout gathers momentum and the data goes stale for early entries, scan these fresh ideas and act while conditions remain current.

• Rotate into steadier candidates that still aim for upside by checking the 2 resilient stocks with low risk scores before those resilient stories get fully caught by the crowd.
• Hunt for income opportunities that try to balance yield with staying power through the 1 dividend fortresses while those payouts and share prices are still under the radar.
• Target potential compounding machines with disciplined balance sheets by using the list of solid balance sheet and fundamentals (10 results) before any quality premium moves beyond a comfortable entry point.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com